SWOG S1007 A Phase III, Randomized Clinical
Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with
1-3 Positive Nodes, Hormone Receptor-Positive and Her-2 Negative Breast Cancer
with Recurrence Score (RS) of 25 or Less
The purpose of
this study is to find out if the Oncotype DX® Recurrence Score can help decide
whether patients should receive chemotherapy or not. This study is being done in patients with
lower Recurrence Scores (25 or less).
Recurrence Score: The Oncotype DX® is a test that looks at multiple genes related to
breast cancer. The combination of the
test results produces a score that is useful in guiding treatment choices for
patients with node-negative breast cancer. The higher the score is, the more likely that the patient’s breast
cancer will come back after surgery.